Aurobindo Pharma's subsidiary, Eugia Pharma, gets USFDA nod for cancer drug Pazopanib. The drug treats renal cell carcinoma and soft tissue sarcoma. Launch expected in Q4FY25. The market size is estimated at USD 106 million. Aurobindo's shares closed slightly lower on Thursday. The drug is a generic version of Novartis's Votrient.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AgyuYNZ
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» Aurobindo unit gets USFDA nod for generic cancer drug
0 comments:
Post a Comment